The Innovation Pipeline features academic innovators, pre-seed stage and early seed stage companies working on incredible, cutting edge science. They have been selected to highlight their discoveries at the Life Sciences Summit and the featured innovators will be available for discussions throughout the live event – meetings may be scheduled via the event partnering system.
2023 Participants
Check back often as participants are being added every week
 |
Blood Cell Technologies, Setauket, NY: Commercializing novel drug targets and compounds that may be used to diagnose or treat blood cell disorders with an initial focus on a redox-inhibiting compound to enhance platelet production in humans. |
 |
Chronus Pharmaceuticals, Inc., Stony Brook, NY: Developing a PET radiotracer that can detect deep seated bacterial infection, thus improving the diagnosis and treatment of diseases such as osteomyelitis, infective endocarditis, and indwelling device infections, which are a major cause of morbidity and financial costs. |
 |
A first-in-class small molecule as a therapy for Ulcerative Colitis: A steroid-sparing, small molecule therapy to treat moderate to severe Ulcerative Colitis. It targets inflammation for long term remission and improved quality of life. |
|
Treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Targeting the Prostaglandin Transporter PGT: First-in-class small molecules targeting novel drug target to treat NAFLD and NASH at all stages of fibrosis. The technology is further differentiated from others in engaging multiple pathways in disease development thereby blocking all escape routes. |
 |
EndoCare, New York, NY: An AI-driven system that offers a non-invasive, objective, and accessible solution for early-stage detection of superficial peritoneal lesions in endometriosis. EndoCare significantly reduces diagnostic disparities, enhances patient outcomes, and democratizes access to quality care for all women, regardless of their background. |
 |
HapticHeart Solutions, New York, NY: Developing a haptic wearable system to provide touch and force feedback during catheter-based interventional cardiology procedures. |
 |
Immunaeon, Buffalo, NY: Working directly with patients to augment cancer immunotherapy by preserving immune cells with higher effector functionality prior to the introduction of cytotoxic chemotherapy or immunosuppressive microenvironmental signals caused by disease progression. |
 |
JelikaLite Corp., New York, NY: Developing a home-based therapeutic wearable, data-device feedback system for children with autism. |
 |
Lahara Bio, Stony Brook, NY: An early-stage biotechnology company using cell-specific mechanical vibration to non-invasively improve biomanufacturing outcomes |
 |
Protein Degrader Therapeutics for Intracranial Disease: Technology to target and deliver protein degrader therapeutics across the blood-brain barrier for intracranial diseases. |
|
Diagnostic QR Codes: A universal sensor for diagnosing a broad range of diseases with a single patient sample, using an environmentally sensitive array resembling a conventional QR code. |
 |
PolyNova Cardiovascular Inc., Stony Brook, NY: Developing novel heart valve replacement technology. |
 |
QAS.AI Inc., Buffalo, NY: Harnessing AI-driven software that integrates with image-guided surgical tools to enhance neurovascular treatments. Precisely detects inadequate brain blood flow during surgery and predicts aneurysm treatment outcomes, optimizing real-time surgical decisions. Collaborative efforts focus on expanding angiographic software and building corporate partnerships. |
 |
RyvivyR, Stony Brook, NY: Stony Brook University Spin-out developing AI-driven methods that modulate approved neurostimulation hardware to personalize treatments for neurological disorders to individuals who are not responsive to traditional treatments, while simultaneously accounting for the complexity of neural dynamics in real-time. |
 |
Selectin Therapeutics, New York, NY: Advancing proprietary nanoparticle technologies developed at Memorial Sloan Kettering Cancer Center and Tel Aviv University designed to ferry drugs across the blood brain barrier specifically at the site of disease by targeting the protein P-selectin on the vascular endothelium. |
 |
Skinterest, New York, NY: A joint venture between two women of color committed to breaking barriers for dermatology care of patients of color. |
 |
Prism PET: A state-of-the-art, plug and play PET detector module which drastically improves the spatial resolution and introduces depth of interaction when incorporated into traditional PET imaging systems. |
|
High Efficiency X-ray Detector: A solid state radiation detector that yields images with much higher resolution than conventional radiation detectors and solid-state imaging detectors. These detectors have ultrafast photo-response and ultra-high time resolution, which significantly improves imaging when observing functional processes within the human body. |
|
3D Facial Scanner: A high-performance 3D camera system and cloud-based, AI-enabled 3D image analysis software for healthcare, cosmetics, orthodontics and other industries. |
 |
Surgical Props, LLC, Stony Brook, NY: Creating and commercializing innovative surgical tools for both minimally invasive and open surgery. Our UNILOOP(TM) single-handed ligating loop device reduces time in the OR and improves patient safety. |
 |
SynchroPET, Stony Brook, NY: SynchroPET builds the smallest most versatile PET Scan devices in the world which are MRI compatible. Their technology is used in conjunction with existing PET and MRI devices to make the existing devices more accurate and useful for both the pre clinical and clinical markets. |
 |
Thylacine Biotherapeutics, New York, NY: Developing a rapid response, broad spectrum antiviral platform utilizing novel lipopeptides engineered to target endemic respiratory viruses of concern, as well as pathogens that may cause future outbreaks; treating illness, limiting transmission, and preventing infection. |
 |
Vicora, Buffalo, NY: Developing the only catheter capable of vibrating at the distal end with an Electroactive Polymer (EAP) Actuator that can be successfully integrated into catheters. |